CN104884089A - 包含单一可变域和甲磺酸卡莫司他(cm)的组合物 - Google Patents

包含单一可变域和甲磺酸卡莫司他(cm)的组合物 Download PDF

Info

Publication number
CN104884089A
CN104884089A CN201380044476.9A CN201380044476A CN104884089A CN 104884089 A CN104884089 A CN 104884089A CN 201380044476 A CN201380044476 A CN 201380044476A CN 104884089 A CN104884089 A CN 104884089A
Authority
CN
China
Prior art keywords
composition
variable domain
single variable
dab
protease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380044476.9A
Other languages
English (en)
Chinese (zh)
Inventor
S.M.克利夫兰
S.萨洛蒙
C.范克林克斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CN104884089A publication Critical patent/CN104884089A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201380044476.9A 2012-08-21 2013-08-21 包含单一可变域和甲磺酸卡莫司他(cm)的组合物 Pending CN104884089A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261691443P 2012-08-21 2012-08-21
US61/691,443 2012-08-21
PCT/IB2013/001814 WO2014030049A2 (en) 2012-08-21 2013-08-21 Compositions comprising a single variable domain and camostat mesylate (cm)

Publications (1)

Publication Number Publication Date
CN104884089A true CN104884089A (zh) 2015-09-02

Family

ID=49510445

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380044476.9A Pending CN104884089A (zh) 2012-08-21 2013-08-21 包含单一可变域和甲磺酸卡莫司他(cm)的组合物

Country Status (11)

Country Link
US (1) US20150306058A1 (enExample)
EP (1) EP2887960A2 (enExample)
JP (1) JP2015527357A (enExample)
KR (1) KR20150043342A (enExample)
CN (1) CN104884089A (enExample)
AU (1) AU2013304627A1 (enExample)
BR (1) BR112015003851A2 (enExample)
CA (1) CA2882684A1 (enExample)
IN (1) IN2015DN01147A (enExample)
RU (1) RU2015110027A (enExample)
WO (1) WO2014030049A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108473585A (zh) * 2015-11-18 2018-08-31 默沙东公司 Pd1和/或lag3结合剂
CN109152738A (zh) * 2016-03-31 2019-01-04 韦斯夸尔德有限公司 组合物

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
BR112017010793A2 (pt) * 2014-11-24 2017-12-26 Regeneron Pharma animal não humano geneticamente modificado, camundongo, métodos para produzir um animal não humano geneticamente modificado e de triagem de candidatos a fármaco direcionados a um antígeno de interesse, e, modelo de camundongo.
AU2016239949A1 (en) 2015-03-31 2017-09-07 Sorriso Pharmaceuticals, Inc. Peptide construct having a protease-cleavable linker
WO2016156468A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptides
ES2984656T3 (es) * 2015-05-13 2024-10-30 Ablynx Nv Polipéptidos que reclutan linfocitos T en función de la reactividad a CD3
BR112018012352A2 (pt) 2015-12-16 2018-12-11 Merck Sharp & Dohme Corp. anticorpos anti-lag3 e fragmentos de ligação ao antígeno
CA3144566A1 (en) 2019-06-21 2020-12-24 Sorriso Pharmaceuticals, Inc. Polypeptides
US12570736B2 (en) 2019-06-21 2026-03-10 Sorriso Pharmaceuticals, Inc. Compositions
JP7692844B2 (ja) 2019-06-21 2025-06-16 ソリッソ ファーマシューティカルズ，インク． ポリペプチド
CA3171958A1 (en) * 2020-03-18 2021-09-23 Memorial Sloan Kettering Cancer Center Inhalational therapy for covid-19

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HIDEYUKI TOZAKI等: "Enhanced Absorption of Insulin and (Asu1,7)Eel-Calcitonin using Novel Azopolymer-Coated Pellets for Colon-Specific Drug Delivery", 《JOURNAL OF PHARMACEUTICAL SCIENCE》 *
HIDEYUKI TOZAKI等: "Use of Protease Inhibitors to Improve Calcitonin Absorption form the Small and Large Intestine in Rats", 《J.PHARM.PHARMACOL》 *
M.M.HARMSEN等: "Escherichia coli F4 fimbriae specific llama single-domain antibody fragments effectively inhibit bacterial adhesion in vitro but poorly protect against diarrhoea", 《VETERINARY MICROBIOLOGY》 *
MARIA DORLY DEL CURTO等: "Oral Delivery System for Two-pulse Colonic Release of Protein Drugs and Protease Inhibitor/Absorption Enhancer Compounds", 《JOURNAL OF PHARMACEUTICAL SCIENCE》 *
MARIA DORLY DEL CURTO等: "Preparation and Evaluation of an Oral Delivery System for Time-Dependent Colon Release of Insulin and Selected Protease Inhibitor and Absorption Enhancer Compounds", 《JOURNAL OF PHARMACEUTICAL SCIENCE》 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108473585A (zh) * 2015-11-18 2018-08-31 默沙东公司 Pd1和/或lag3结合剂
CN108473585B (zh) * 2015-11-18 2022-04-05 默沙东公司 Pd1和/或lag3结合剂
CN109152738A (zh) * 2016-03-31 2019-01-04 韦斯夸尔德有限公司 组合物
CN109152738B (zh) * 2016-03-31 2023-10-13 索里索制药公司 组合物
CN117243904A (zh) * 2016-03-31 2023-12-19 索里索制药公司 组合物

Also Published As

Publication number Publication date
BR112015003851A2 (pt) 2017-08-08
JP2015527357A (ja) 2015-09-17
CA2882684A1 (en) 2014-02-27
WO2014030049A2 (en) 2014-02-27
KR20150043342A (ko) 2015-04-22
IN2015DN01147A (enExample) 2015-06-26
EP2887960A2 (en) 2015-07-01
RU2015110027A (ru) 2016-10-10
US20150306058A1 (en) 2015-10-29
WO2014030049A3 (en) 2014-04-17
AU2013304627A1 (en) 2015-02-26

Similar Documents

Publication Publication Date Title
US20150306058A1 (en) Composition comprising a single variable domain and camostat mesylate (cm)
US20240254180A1 (en) Compositions of peptide inhibitors of interleukin-23 receptor
Joyce et al. Bile acid modifications at the microbe-host interface: potential for nutraceutical and pharmaceutical interventions in host health
JP7057360B2 (ja) 抗－ｃｄ３抗体製剤
AU2018318132A1 (en) Compositions and methods for treating cholestatic disease
JP2024544920A (ja) イオン液体組成物
Chakraborty et al. Conjugated bile acids are nutritionally re-programmable antihypertensive metabolites
JP2023509790A (ja) α４β７インテグリン拮抗薬で炎症性腸疾患を治療するための方法
Crona et al. Gastrointestinal hormone concentrations associated with gastric feeding in critically ill patients
AU2026201037A1 (en) Methods for treating metabolic diseases by inhibiting myostatin activation
JP2022513176A (ja) オキシントモジュリンペプチド類似体製剤
AU2018360382A1 (en) Oral delivery of GLP-1 peptide analogs
US20230050846A1 (en) Treatment of hepatic and cardiovascular disorders
CN104884469A (zh) 包含抗体和甲磺酸卡莫司他(cm)的组合物
KR20170134751A (ko) 심혈관 질환의 치료 방법
US20150291662A1 (en) Modified peptide, cb receptor ligand, kit in vitro process for evaluating cb receptor bonds, uses, pharmaceutical composition for modulating cb receptor activity
CN101068560B (zh) 毒素中和性肽的筛选方法和STX2抑制性肽以及Vero毒素中和剂
US9913850B2 (en) Bile acids and biguanides as protease inhibitors for preserving the integrity of peptides in the gut
US20250277042A1 (en) TREATMENT OF PRURITIS EMPLOYING ANTI-IL13Ra1 ANTIBODY OR BINDING FRAGMENT THEREOF
WO2009053725A2 (en) Peptides and uses thereof
WO2025228328A1 (zh) 一种两性离子多肽载体及其在跨屏障药物递送中的应用
HK40108093A (en) Long-acting dual gip/glp-1 peptide conjugates and methods of use
CN121909036A (zh) 用于治疗代谢、心血管、炎性和肿瘤疾病的产品和方法
CN113912700A (zh) Claudin-18.2抗原多肽疫苗及其应用
Hellerstein et al. Seladelpar combined with complementary therapies improves fibrosis, inflammation and liver 4 injury in a mouse model of nonalcoholic steatohepatitis 5

Legal Events

Date Code Title Description
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150902